Sentence examples for mutations and gain from inspiring English sources

Patients with higher HER2 copy numbers, a combination of mutations and gain of PIK3CA, and gain of MYBL2 and AIB1 had or tended to have worse pCR and RFS rates than the respective counterparts (Table 3).

However, we believe that tumors bearing high levels of COUP-TFII will be resistant to growth inhibitory effects caused by TGF-β signaling and will enable the tumor cells to accumulate mutations and gain metastatic potential.

Tumors with a combination of mutations and gain of PIK3CA, or combined aberrations of the PI3K pathway genes, PIK3CA, PTEN and INPP4B tended to have more difficulty entering pCR than tumors without (P=0.08 and P=0.086).

Patients having a HR+ tumor with mutations of PIK3CA (P=0.006), a combination of mutations and gain of PIK3CA (P=0.001), a combined aberration of PIK3CA, PTEN and INPP4B (P=0.002), and gain of FOXA1 (P=0.002), CDH3 (P=0.007), BIRC5 (P=0.016), MYBL2 (P=0.015), and AIB1 (P=0.006) had worse RFS rates than patients having a HR+ tumor without (Table 4).

When the prognostic implications of the genetic aberrations were separately examined in HR+ and HR- tumors, a combination of mutations and gain of PIK3CA, a combined aberration of the PI3K pathway genes, and gain of FOXA1, CDH3, BIRC5, MYBL2, and AIB1 indicated worse RFS rates only in patients with a HR+ tumor (Table 4).

Although this phenotype has been described in Brugada syndrome due to Na+ channel mutations and gain-of-function Kv11.1 mutant channels [39], it has not been previously reported with dominant-negative Kv11.1 mutations associated with LQT2.

This view is strengthened by the association of cluster B2 with scar-like tumor fibrosis, a desmoplastic reaction which is common in localized peripheral lung adenocarcinoma, and of cluster B3 with the highest rate of EGFR mutation (93%) as well as the highest rate of the co-occurrence of EFGR mutations and gains or amplifications on 7p (86%).

Given that X chromosome dosage compensation is very close to two-fold, whereas the effect of MSL mutations and gain-of-function are not, and given that the X does not appear to show boosted gene-by-gene compensation, then a substantial amount of X chromosome dosage compensation remains unexplained.

Only four cases in the whole study had both a mutation and gain of copy number of PIK3CA.

To determine the relation between somatic mutation and gain of gene copy number of PIK3CA gene in breast cancer, we integrated our mutation and gene copy number data.

We did not observe a significant association between somatic mutation and gain of PIK3CA gene copy number in 92 cases of breast tumors (Table 2).